<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097846</url>
  </required_header>
  <id_info>
    <org_study_id>2021HP</org_study_id>
    <nct_id>NCT05097846</nct_id>
  </id_info>
  <brief_title>Differences in the Eradication of Helicobacter Pylori by Different Therapies</brief_title>
  <official_title>Comparison of Vonoprazan Fumarate-based Triple Therapy Versus Proton Pump Inhibitor and Bismuth Based Quadruple Therapy in the Eradication of Helicobacter Pylori: a Single-center Prospective Open-label Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>wang xiaoyan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the performance of four treatment regimens for radical treatment of Helicobacter&#xD;
      pylori, evaluating the efficacy, safety, patient compliance, and socioeconomic evaluation of&#xD;
      the four regimens. The four treatment regimens included (1) Vonoprazan Fumarate + amoxicillin&#xD;
      + doxycycline, (2) Vonoprazan Fumarate + furazolidone + doxycycline, (3) esomeprazole +&#xD;
      colloidal bismuth tartrate + amoxicillin + doxycycline, and (4) esomeprazole + colloidal&#xD;
      bismuth tartrate + furazolidone + doxycycline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center, prospective, open-label, parallel control design was conducted to enroll 100&#xD;
      patients with confirmed Helicobacter pylori infection. Patients were randomly divided into&#xD;
      four groups, respectively accept four treatment regimens including (1) Vonoprazan Fumarate +&#xD;
      amoxicillin + doxycycline, (2) Vonoprazan Fumarate + furazolidone + doxycycline, (3)&#xD;
      esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline, and (4) esomeprazole +&#xD;
      colloidal bismuth tartrate + furazolidone + doxycycline. The effectiveness, safety and&#xD;
      compliance of the four regimens were compared, and the cost-benefit analysis of the different&#xD;
      regimens was conducted. The purpose of this study was to explore the most appropriate&#xD;
      treatment plan for radical treatment of Helicobacter pylori .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Hp at one time</measure>
    <time_frame>43 or 57 days after the initiation of eradication therapy</time_frame>
    <description>The UBT test was performed to determine whether Hp was eradicated. No antibiotics, bismuth, or PPI were taken during this period. ITT analysis and PP analysis were used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-benefit analysis</measure>
    <time_frame>43 or 57 days after the initiation of eradication therapy</time_frame>
    <description>The drug cost of the two treatment options was calculated. According to the HP eradication rate, markov model was used to conduct cost-benefit analysis of the two methods, and determine which method was more cost-effective from an economic perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>43 or 57 days after the initiation of eradication therapy</time_frame>
    <description>Adverse drug events, significant laboratory outliers, and new diseases emerging during the study</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Group1: Vonoprazan Fumarate + amoxicillin + doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2: Vonoprazan Fumarate + furazolidone + doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group1 Vonoprazan Fumarate + amoxicillin + doxycycline</intervention_name>
    <description>Vonoprazan Fumarate + amoxicillin + doxycycline</description>
    <arm_group_label>Group1: Vonoprazan Fumarate + amoxicillin + doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group2 Vonoprazan Fumarate + furazolidone + doxycycline</intervention_name>
    <description>Vonoprazan Fumarate + furazolidone + doxycycline</description>
    <arm_group_label>Group2: Vonoprazan Fumarate + furazolidone + doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline</intervention_name>
    <description>esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline</description>
    <arm_group_label>Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline</intervention_name>
    <description>esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline</description>
    <arm_group_label>Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years, ≤80 years&#xD;
&#xD;
          2. Urea breath test (UBT) was positive for Hp infection;&#xD;
&#xD;
          3. WIthout any anti-Hp treatment before&#xD;
&#xD;
          4. Endoscopy was performed within 1 month&#xD;
&#xD;
          5. Understanding the purpose and procedure of the study, voluntarily participating in the&#xD;
             study and signing a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to drugs used in this clinical study;&#xD;
&#xD;
          2. Using PPI, histamine H2 receptor antagonist, antibiotics, bismuth, probiotics or drugs&#xD;
             with antibacterial effects within 4 weeks before treatment.&#xD;
&#xD;
          3. Using adrenal corticosteroids, non-steroidal anti-inflammatory drugs and&#xD;
             anticoagulants&#xD;
&#xD;
          4. The disease or clinical condition that may interfere with the treatment evaluation of&#xD;
             the study, such as liver disease, cardiovascular disease, lung disease, kidney&#xD;
             disease, metabolic disease, psychiatric disease, or malignant tumor&#xD;
&#xD;
          5. Pregnant or lactating women&#xD;
&#xD;
          6. Participated in other clinical studies within 3 months prior to the registration of&#xD;
             this clinical study&#xD;
&#xD;
          7. Suspected history of antibiotic abuse&#xD;
&#xD;
          8. Patients with craniocerebral injury, mental illness or epilepsy who cannot communicate&#xD;
             with others or other diseases that may affect follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyan Wang, MD,PhD</last_name>
    <phone>+8613974889301</phone>
    <email>wangxiaoyan@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zinan Zhang, MD</last_name>
    <phone>+8615273169959</phone>
    <email>classroom0705@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The third Xiangya Hospital of central south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Wang, MD</last_name>
      <phone>+8613974889301</phone>
      <email>wangxiaoyan@csu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zinan Zhang, MD</last_name>
      <phone>+8615273169959</phone>
      <email>classroom0705@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Third Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>wang xiaoyan</investigator_full_name>
    <investigator_title>Director, Head of Gastroenterology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT05097846/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

